Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2007 Oct 23;8(5):283–288. doi: 10.1007/s10194-007-0417-4

Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine

Mario Guidotti 1,✉, Michela Mauri 1, Caterina Barrilà 1, Francesca Guidotti 1, Carlo Belloni 2
PMCID: PMC3476156  PMID: 17955167

Abstract

Acute treatment of menstrual migraine (MM) attacks is often incomplete and unsatisfactory, and perimenstrual prophylaxis with triptans, oestrogen supplementation or naproxen sodium may be needed for decreasing frequency and severity of the attack. In this pilot, open-label, non-randomised, parallel group study we evaluated, in 38 women with a history of MM, the efficacy of frovatriptan (n=14) 2.5 mg per os or transdermal oestrogens (n=10) 25 μg or naproxen sodium (n=14) 500 mg per os once-daily for the short-term prevention of MM. All treatments were administered in the morning for 6 days, beginning 2 days before the expected onset of menstrual headache. All women were asked to fill in a diary card, in the absence of (baseline) and under treatment, in order to score headache severity. All women reported at least one episode of MM at baseline. During treatment all patients taking transdermal oestrogens or naproxen sodium and 13 out of the 14 patients (93%) taking frovatriptan had at least one migraine attack (p=0.424). Daily incidence of migraine was significantly (p=0.045) lower under frovatriptan than under transdermal oestrogens or NS. At baseline, the overall median score of headache severity was 4.6, 4.2 and 4.3 in the group subsequently treated with frovatriptan, transdermal oestrogens and naproxen sodium, respectively (p=0.819). During treatment the median score was significantly lower under frovatriptan (2.5) than under transdermal oestrogens (3.0) and naproxen sodium (3.9, p=0.049). This was evident also for each single day of observation (p=0.016). Among treatments differences were particularly evident for the subgroup of patients with true MM (n=22) and for frovatriptan vs. naproxen sodium. This study suggests that short-term prophylaxis of MM with frovatriptan may be more effective than that based on transdermal oestrogens or naproxen sodium.

Keywords: Frovatriptan, Menstrual migraine, Transdermal oestrogens, Naproxen sodium, True menstrual migraine, Menstrually related migraine

Full Text

The Full Text of this article is available as a PDF (374.9 KB).

References

  • 1.Lipton R.B., Bigal M.E., Diamond M., Freitag F., Reed M.L., Stewart W.F. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349. doi: 10.1212/01.wnl.0000252808.97649.21. [DOI] [PubMed] [Google Scholar]
  • 2.Breslau N., Rasmussen B.K. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology. 2001;56([6Suppl1]):4–12. doi: 10.1212/wnl.56.suppl_1.s4. [DOI] [PubMed] [Google Scholar]
  • 3.Brandes J.L. The influence of estrogen on migraine: a systematic review. JAMA. 2006;295:1824–1830. doi: 10.1001/jama.295.15.1824. [DOI] [PubMed] [Google Scholar]
  • 4.Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders. Cephalalgia. 2004;24([Suppl.1]):1–160. [Google Scholar]
  • 5.Granella F., Sances G., Allais G., Nappi R.E., Tirelli A., Benedetto C., et al. Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707–716. doi: 10.1111/j.1468-2982.2004.00741.x. [DOI] [PubMed] [Google Scholar]
  • 6.Allais G., Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol Sci. 2004;25([Suppl3]):229–231. doi: 10.1007/s10072-004-0292-6. [DOI] [PubMed] [Google Scholar]
  • 7.Mannix L.K. Management of menstrual migraine. Neurologist. 2003;9:207–213. doi: 10.1097/01.nrl.0000080952.78533.0a. [DOI] [PubMed] [Google Scholar]
  • 8.Ashkenazi A., Silberstein S.D. Hormone-related headache: pathophysiology and treatment. CNS Drugs. 2006;20:125–141. doi: 10.2165/00023210-200620020-00004. [DOI] [PubMed] [Google Scholar]
  • 9.MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15([Suppl3]):143–153. [PubMed] [Google Scholar]
  • 10.Martin V. Targeted treatment strategies for menstrual migraine. J Fam Pract. 2007;56:13–22. [PubMed] [Google Scholar]
  • 11.Silberstein S.D., Elkind A.H., Schreiber C., Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–269. doi: 10.1212/01.wnl.0000134620.30129.d6. [DOI] [PubMed] [Google Scholar]
  • 12.Newman L., Mannix L.K., Landy S., Silberstein S., Lipton R.B., Putnam D.G., et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41:248–256. doi: 10.1046/j.1526-4610.2001.111006248.x. [DOI] [PubMed] [Google Scholar]
  • 13.Newman L.C., Lipton R.B., Lay C.L., Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307–309. doi: 10.1212/wnl.51.1.307. [DOI] [PubMed] [Google Scholar]
  • 14.Moschiano F., Allais G., Grazzi L., Usai S., Benedetto C., D’Amico D., et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci. 2005;26([Suppl2]):162–166. doi: 10.1007/s10072-005-0435-4. [DOI] [PubMed] [Google Scholar]
  • 15.Allais G., Bussone G., Lorenzo C., Mana O., Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci. 2005;26([Suppl2]):125–129. doi: 10.1007/s10072-005-0424-7. [DOI] [PubMed] [Google Scholar]
  • 16.Geraud G., Spierings E.L., Keywood C. Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42([Suppl2]):93–99. doi: 10.1046/j.1526-4610.42.s2.7.x. [DOI] [PubMed] [Google Scholar]
  • 17.Belsey E.M., Farley T.M. The analysis of menstrual bleeding patterns: a review. Contraception. 1988;38:129–156. doi: 10.1016/0010-7824(88)90035-2. [DOI] [PubMed] [Google Scholar]
  • 18.Smits M.G., Meer Y.G., Pfeil J.P., Rijnierse J.J., Vos A.J. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34:103–106. doi: 10.1111/j.1526-4610.1994.hed3402103.x. [DOI] [PubMed] [Google Scholar]
  • 19.Sances G., Martignoni E., Fioroni L., Blandini F., Facchinetti F., Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705–709. doi: 10.1111/j.1526-4610.1990.hed3011705.x. [DOI] [PubMed] [Google Scholar]
  • 20.Pradalier A., Vincent D., Beaulieu P., Baudesson G., Launay J. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Rose C., editor. New Advances in Headache Research. London: Smith-Gordon; 1994. pp. 129–132. [Google Scholar]
  • 21.Pfaffenrath V.L. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia. 1993;13([suppl]):244–247. [Google Scholar]
  • 22.Smits M.G., Meer Y.G., Pfeil J.P., Rijnierse J.J., Vos A.J. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34:103–106. doi: 10.1111/j.1526-4610.1994.hed3402103.x. [DOI] [PubMed] [Google Scholar]
  • 23.MacGregor E.A. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354–361. doi: 10.1016/S1474-4422(04)00768-9. [DOI] [PubMed] [Google Scholar]
  • 24.Nappi R.E., Sances G., Brundu B., Taddei S., Sommacal A., Ghiotto N., et al. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod. 2005;20:3423–3428. doi: 10.1093/humrep/dei260. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES